biostudies-literatureManocha NSenior Research Fellowship from the Indian Council of Medical Research (ICMR), New DelhiEuropean Molecular Biology Organization (EMBO) Scientific Exchange316https://www.ebi.ac.uk/biostudies/studies/S-EPMC10975250biostudies-literatureUnknown12(3)Dengue virus (DENV) infection continues to be a public health challenge, lacking a specific cure. Vaccination remains the primary strategy against dengue; however, existing live-attenuated vaccines display variable efficacy across four serotypes, influenced by host serostatus and age, and predominantly inducing humoral responses. To address this limitation, this study investigates a multiepitope-based immunogen designed to induce robust cellular immunity across all DENV serotypes. The chimeric immunogen integrates H-2^d specific MHC-I binding T-cell epitopes derived from conserved domains within the DENV envelope protein. Immuno-informatics analyses supported its stability, non-allergenic nature, and strong MHC-I binding affinity as an antigen. To assess the immunogenicity of theVaccinesUnveiling a Shield of Hope: A Novel Multiepitope-Based Immunogen for Cross-Serotype Cellular Defense against Dengue Virus.PMC109752509401VIR/Fellowship/35/2019-ECD-IMarvel JManocha NGueguen-Chaignon VGouet PRobert XLaubreton DKumar PKhanna MfalseUnveiling a Shield of Hope: A Novel Multiepitope-Based Immunogen for Cross-Serotype Cellular Defense against Dengue Virus.Dengue virus (DENV) infection continues to be a public health challenge, lacking a specific cure. Vaccination remains the primary strategy against dengue; however, existing live-attenuated vaccines display variable efficacy across four serotypes, influenced by host serostatus and age, and predominantly inducing humoral responses. To address this limitation, this study investigates a multiepitope-based immunogen designed to induce robust cellular immunity across all DENV serotypes. The chimeric immunogen integrates H-2^d specific MHC-I binding T-cell epitopes derived from conserved domains within the DENV envelope protein. Immuno-informatics analyses supported its stability, non-allergenic nature, and strong MHC-I binding affinity as an antigen. To assess the immunogenicity of the2024-01-01T00:00:00Z2024 Mar2026-07-09T11:06:51.175Z2026-07-09T10:38:09.494ZS-EPMC109752503854395010.3390/vaccines12030316